List of Figures

Figure 1.1 : National prevalence of diabetes and number of diabetes related deaths during 2011
Figure 1.2 : Formation of advanced glycation end products (AGEs)
Figure 1.3 : Various fluorescent and non fluorescent AGEs
Figure 1.4 : AGE modified proteins in CICs and their involvement in pathogenesis
Figure 1.5 : Bar graph depicts the quantity of serum albumin in CICs from clinical plasma samples (Label-free-based MS quantification of CICs)
Figure 2.2a : Western blotting analysis of CICs using anti-serum albumin antibody
Figure 2.2b : Figure 2.2b Western blotting analysis for AGE modification of serum albumin in CICs, using Anti-AGE antibodies
Figure 2.3 : Manually annotated AGE modified peptide of HSA, identified in CICs
Figure 2.4 : Evaluation of potential non specific binding of HSA
Figure 2.5 : Bar graph depicts average intensity of fluorescent AGEs
Figure 2.6 : Western blotting analysis of total plasma proteins for AGEs in clinical samples
Figure 3.1 : Bar graph depicting average intensity of fluorescent AGEs in mice plasma
Figure 3.2 : Western blotting analysis of total plasma proteins using anti-AGE antibodies
Figure 3.3 : Heatmap showing relative quantification of AGE-modified peptides in serum albumin from mice plasma
Figure 3.4 : Manually annotated AGE modified peptide of MSA, identified from mice plasma
Figure 3.5 : Bar graph depicts quantity of serum albumin in CICs from mice plasma samples
Figure 3.6a : Western blotting analysis of CICs using anti-serum albumin antibodies
Figure 3.6b : Anti-AGE Western blot of CICs from mice plasma
Figure 3.7 : Manually annotated AGE modified peptide of MSA identified in CICs
Figure 3.8 : Relative fold change of CIC associated proteins
Figure 3.9a : Manually annotated AGE modified peptide of Alpha 1 antitrypsin A1 associated with CICs
Figure 3.9b : Manually annotated AGE modified peptide of Apolipoprotein A1 associated with CICs
Figure 3.9c : Manually annotated AGE modified peptide of Apolipoprotein E associated with CICs
Figure 3.9d : Manually annotated AGE modified peptide of Carboxylesterase C associated with CICs
Figure 3.9e : Manually annotated AGE modified peptide of Alpha 2 macroglobulin associated with CICs
Figure 3.9 : Graphical representation of total plasma albumin estimated by BCG method
Figure 3.10 : Measurement of cytokines in mice plasma. Bar graph depicting cytokines in...
mice plasma samples

**Figure 3.11**: Study overview

**Figure 4.1**: Graphical representation of antibody titre against CML-MSA and unmodified MSA (C-MSA) in mice plasma

**Figure 4.2**: Heatmap showing relative quantification of AGE-modified peptides albumin from mice plasma

**Figure 4.3**: Manually annotated AGE modified peptide of MSA, identified from mice plasma

**Figure 4.4**: Label-free-based MS quantification revealed increased CIC albumin in C-IMP mice compared with that of C-ICP

**Figure 4.5**: Western blotting analysis of CICs using anti-serum albumin antibodies

**Figure 4.6**: Anti-AGE Western blot of CICs from mice plasma

**Figure 4.7**: Measurement of cytokines in mice plasma. Bar graph depicting cytokines in plasma samples from C-ICP and C-IMP mice (Significant difference)

**Figure 4.8**: Measurement of cytokines in mice plasma. Bar graph depicting cytokines in plasma samples from C-ICP and C-IMP mice (significantly not different)

**Figure 4.9**: Graphical representation of total plasma albumin estimated by BCG method